Highlights Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Market Closed - Nasdaq Other stock markets 21:00:00 14/05/2024 BST			5-day change	1st Jan Change
35.09 ^USD	-8.52%		-8.71%	+37.82%

05-03	Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53	MT
05-02	Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises	05-02	MT
Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Kymera Therapeutics, Inc. Provides Business Highlights and Updates on Its Pipeline of Protein Degraders	05-02	CI
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting	04-08	CI
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting	03-08	CI
Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises	02-22	MT
Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Kymera Therapeutics, Inc. Intends to Initiate A Phase 1 Clinical Trial in the Second Half of 2024 and Report the Phase 1 Results in 2025	01-04	CI
Kymera Therapeutics, Inc. Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting	12-11	CI
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474p	12-07	CI
Kymera Therapeutics, Inc. Announces Publication of Phase 1 Trial Results for KT-474, a First-In-Class IRAK4 Degrader, in Nature Medicine	11-13	CI
Kymera Therapeutics, Inc. to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting	11-02	CI
Kymera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Kymera Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474	27/10/23	CI
Kymera Therapeutics, Inc. Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma	16/10/23	CI
Kymera Therapeutics Secures US FDA Fast Track Designation for Potential Lymphoma Treatment	18/09/23	MT
Kymera Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma	18/09/23	CI
Kymera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Kymera Therapeutics Says US FDA Grants Orphan Drug Designation for KT-253 to Treat Acute Myeloid Leukemia	22/06/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Highlights

Filters